Tehran University of Medical Sciences Iranian Journal of Public Health 2251-6085 46 7 2017 06 25 982 984 Abbas ZAMANIAN Rasoul-e-Akram Hospital, Iran University of Medical Sciences, Tehran, Iran Atefeh GHANBARI JOLFAEI Dept. of Psychiatry, Iran University of Medical Sciences, Tehran, Iran Golnaz MEHRAN Rasoul-e-Akram Hospital, Iran University of Medical Sciences, Tehran, Iran Zahra AZIZIAN Rasoul-e-Akram Hospital, Iran University of Medical Sciences, Tehran, Iran AND Skin and Stem Cell Research Center, Tehran University of Medical Sciences, Tehran, Iran 2017 06 25 2017 06 25 Background: Treatment of major depression is crucial to decrease the burden of disease. Hence, in this study, the efficacy of Botox was compared with placebo for treatment of patients with major depression. Methods: In this randomized clinical trial, 28 consecutive patients with major depression were enrolled. The patients were randomly assigned to receive either Botox or placebo and the scores of Beck Depression Inventory were determined and compared at baseline and after two and six weeks in the groups and between the groups. In addition, the drug adverse effects were compared between groups. This study had been registered in TCTR with TCTR20170409001 code. Results: There was a statistically significant difference two group for 6th week Beck Score (P=0.004), but at baseline and after two weeks, there was no significant difference (P>0.05). None of the patients experienced side effects. Conclusion: Finally, Botox is effective for treatment of patients with major depression and it has a high safety.     https://ijph.tums.ac.ir/index.php/ijph/article/view/10403 https://ijph.tums.ac.ir/index.php/ijph/article/download/10403/5801